In Lysinuric Protein Intolerance system y+L activity is defective in monocytes and in GM-CSF-differentiated macrophages
Tóm tắt
In the recessive aminoaciduria Lysinuric Protein Intolerance (LPI), mutations of SLC7A7/y+LAT1 impair system y+L transport activity for cationic amino acids. A severe complication of LPI is a form of Pulmonary Alveolar Proteinosis (PAP), in which alveolar spaces are filled with lipoproteinaceous material because of the impaired surfactant clearance by resident macrophages. The pathogenesis of LPI-associated PAP remains still obscure. The present study investigates for the first time the expression and function of y+LAT1 in monocytes and macrophages isolated from a patient affected by LPI-associated PAP. A comparison with mesenchymal cells from the same subject has been also performed. Monocytes from peripheral blood were isolated from a 21-year-old patient with LPI. Alveolar macrophages and fibroblastic-like mesenchymal cells were obtained from a whole lung lavage (WLL) performed on the same patient. System y+L activity was determined measuring the 1-min uptake of [3H]-arginine under discriminating conditions. Gene expression was evaluated through qRT-PCR. We have found that: 1) system y+L activity is markedly lowered in monocytes and alveolar macrophages from the LPI patient, because of the prevailing expression of SLC7A7/y+LAT1 in these cells; 2) on the contrary, fibroblasts isolated from the same patient do not display the transport defect due to compensation by the SLC7A6/y+LAT2 isoform; 3) in both normal and LPI monocytes, GM-CSF induces the expression of SLC7A7, suggesting that the gene is a target of the cytokine; 4) GM-CSF-induced differentiation of LPI monocytes is comparable to that of normal cells, demonstrating that GM-CSF signalling is unaltered; 5) general and respiratory conditions of the patient, along with PAP-associated parameters, markedly improved after GM-CSF therapy through aerosolization. Monocytes and macrophages, but not fibroblasts, derived from a LPI patient clearly display the defect in system y+L-mediated arginine transport. The different transport phenotypes are referable to the relative levels of expression of SLC7A7 and SLC7A6. Moreover, the expression of SLC7A7 is regulated by GM-CSF in monocytes, pointing to a role of y+LAT1 in the pathogenesis of LPI associated PAP.
Tài liệu tham khảo
Palacin M, Borsani G, Sebastio G: The molecular bases of cystinuria and lysinuric protein intolerance. Curr Opin Genet Dev. 2001, 11: 328-335. 10.1016/S0959-437X(00)00198-2.
Verrey F, Closs EI, Wagner CA, Palacin M, Endou H, Kanai Y: CATs and HATs: the SLC7 family of amino acid transporters. Pflugers Arch. 2004, 447: 532-542. 10.1007/s00424-003-1086-z.
Borsani G, Bassi MT, Sperandeo MP, De Grandi A, Buoninconti A, Riboni M, Manzoni M, Incerti B, Pepe A, Andria G: SLC7A7, encoding a putative permease-related protein, is mutated in patients with lysinuric protein intolerance. Nat Genet. 1999, 21: 297-301. 10.1038/6815.
Torrents D, Estevez R, Pineda M, Fernandez E, Lloberas J, Shi YB, Zorzano A, Palacin M: Identification and characterization of a membrane protein (y+L amino acid transporter-1) that associates with 4F2 hc to encode the amino acid transport activity y+L. A candidate gene for lysinuric protein intolerance. J Biol Chem. 1998, 273: 32437-32445. 10.1074/jbc.273.49.32437.
Simell O, Perheentupa J, Rapola J, Visakorpi JK, Eskelin LE: Lysinuric protein intolerance. Am J Med. 1975, 59: 229-240. 10.1016/0002-9343(75)90358-7.
Parenti G, Sebastio G, Strisciuglio P, Incerti B, Pecoraro C, Terracciano L, Andria G: Lysinuric protein intolerance characterized by bone marrow abnormalities and severe clinical course. J Pediatr. 1995, 126: 246-251. 10.1016/S0022-3476(95)70552-X.
DiRocco M, Garibotto G, Rossi GA, Caruso U, Taccone A, Picco P, Borrone C: Role of haematological, pulmonary and renal complications in the long-term prognosis of patients with lysinuric protein intolerance. Eur J Pediatr. 1993, 152: 437-440. 10.1007/BF01955906.
Parto K, Svedstrom E, Majurin ML, Harkonen R, Simell O: Pulmonary manifestations in lysinuric protein intolerance. Chest. 1993, 104: 1176-1182. 10.1378/chest.104.4.1176.
Santamaria F, Parenti G, Guidi G, Rotondo A, Grillo G, Larocca MR, Celentano L, Strisciuglio P, Sebastio G, Andria G: Early detection of lung involvement in lysinuric protein intolerance: role of high-resolution computed tomography and radioisotopic methods. Am J Respir Crit Care Med. 1996, 153: 731-735.
Trapnell BC, Carey BC, Uchida K, Suzuki T: Pulmonary alveolar proteinosis, a primary immunodeficiency of impaired GM-CSF stimulation of macrophages. Curr Opin Immunol. 2009, 21: 514-521. 10.1016/j.coi.2009.09.004.
Trapnell BC, Whitsett JA, Nakata K: Pulmonary alveolar proteinosis. N Engl J Med. 2003, 349: 2527-2539. 10.1056/NEJMra023226.
Parto K, Maki J, Pelliniemi LJ, Simell O: Abnormal pulmonary macrophages in lysinuric protein intolerance. Ultrastructural, morphometric, and x-ray microanalytic study. Arch Pathol Lab Med. 1994, 118: 536-541.
Whitsett JA, Wert SE, Weaver TE: Alveolar surfactant homeostasis and the pathogenesis of pulmonary disease. Annu Rev Med. 2010, 61: 105-119. 10.1146/annurev.med.60.041807.123500.
Santamaria F, Brancaccio G, Parenti G, Francalanci P, Squitieri C, Sebastio G, Dionisi-Vici C, D'Argenio P, Andria G, Parisi F: Recurrent fatal pulmonary alveolar proteinosis after heart-lung transplantation in a child with lysinuric protein intolerance. J Pediatr. 2004, 145: 268-272. 10.1016/j.jpeds.2004.04.047.
Rotoli BM, Bussolati O, Sala R, Barilli A, Talarico E, Gazzola GC, Dall'Asta V: INFgamma stimulates arginine transport through system y+L in human monocytes. FEBS Lett. 2004, 571: 177-181. 10.1016/j.febslet.2004.06.086.
Rotoli BM, Dall'asta V, Barilli A, D'Ippolito R, Tipa A, Olivieri D, Gazzola GC, Bussolati O: Alveolar macrophages from normal subjects lack the NOS-related system y+ for arginine transport. Am J Respir Cell Mol Biol. 2007, 37: 105-112. 10.1165/rcmb.2006-0262OC.
Gazzola GC, Dall'Asta V, Guidotti GG: The transport of neutral amino acids in cultured human fibroblasts. J Biol Chem. 1980, 255: 929-936.
Visigalli R, Barilli A, Bussolati O, Sala R, Gazzola GC, Parolari A, Tremoli E, Simon A, Closs EI, Dall'Asta V: Rapamycin stimulates arginine influx through CAT2 transporters in human endothelial cells. Biochim Biophys Acta. 2007, 1768: 1479-1487. 10.1016/j.bbamem.2007.02.016.
Bundey RA, Insel PA: Quantification of adenylyl cyclase messenger RNA by real-time polymerase chain reaction. Anal Biochem. 2003, 319: 318-322. 10.1016/S0003-2697(03)00325-7.
Sperandeo MP, Annunziata P, Ammendola V, Fiorito V, Pepe A, Soldovieri MV, Taglialatela M, Andria G, Sebastio G: Lysinuric protein intolerance: identification and functional analysis of mutations of the SLC7A7 gene. Hum Mutat. 2005, 25: 410-10.1002/humu.9323.
Parini R, Vegni M, Pontiggia M, Melotti D, Corbetta C, Rossi A, Piceni Sereni L: A difficult diagnosis of lysinuric protein intolerance: association with glucose-6-phosphate dehydrogenase deficiency. J Inherit Metab Dis. 1991, 14: 833-834. 10.1007/BF01799959.
Ceruti M, Rodi G, Stella GM, Adami A, Bolongaro A, Baritussio A, Pozzi E, Luisetti M: Successful whole lung lavage in pulmonary alveolar proteinosis secondary to lysinuric protein intolerance: a case report. Orphanet J Rare Dis. 2007, 2: 14-10.1186/1750-1172-2-14.
Duval M, Fenneteau O, Doireau V, Faye A, Emilie D, Yotnda P, Drapier JC, Schlegel N, Sterkers G, de Baulny HO, Vilmer E: Intermittent hemophagocytic lymphohistiocytosis is a regular feature of lysinuric protein intolerance. J Pediatr. 1999, 134: 236-239. 10.1016/S0022-3476(99)70423-3.
Rotoli BM, Closs EI, Barilli A, Visigalli R, Simon A, Habermeier A, Bianchi N, Gambari R, Gazzola GC, Bussolati O, Dall'Asta V: Arginine transport in human erythroid cells: discrimination of CAT1 and 4F2 hc/y+LAT2 roles. Pflugers Arch. 2009, 458: 1163-1173. 10.1007/s00424-009-0692-9.
Dall'Asta V, Bussolati O, Sala R, Rotoli BM, Sebastio G, Sperandeo MP, Andria G, Gazzola GC: Arginine transport through system y(+)L in cultured human fibroblasts: normal phenotype of cells from LPI subjects. Am J Physiol Cell Physiol. 2000, 279: C1829-1837.
Glass CK, Witztum JL: Atherosclerosis. the road ahead. Cell. 2001, 104: 503-516. 10.1016/S0092-8674(01)00238-0.
Bonfield TL, Farver CF, Barna BP, Malur A, Abraham S, Raychaudhuri B, Kavuru MS, Thomassen MJ: Peroxisome proliferator-activated receptor-gamma is deficient in alveolar macrophages from patients with alveolar proteinosis. Am J Respir Cell Mol Biol. 2003, 29: 677-682. 10.1165/rcmb.2003-0148OC.
Thomassen MJ, Barna BP, Malur AG, Bonfield TL, Farver CF, Malur A, Dalrymple H, Kavuru MS, Febbraio M: ABCG1 is deficient in alveolar macrophages of GM-CSF knockout mice and patients with pulmonary alveolar proteinosis. J Lipid Res. 2007, 48: 2762-2768. 10.1194/jlr.P700022-JLR200.
Abe A, Hiraoka M, Wild S, Wilcoxen SE, Paine R, Shayman JA: Lysosomal phospholipase A2 is selectively expressed in alveolar macrophages. J Biol Chem. 2004, 279: 42605-42611. 10.1074/jbc.M407834200.
Hiraoka M, Abe A, Lu Y, Yang K, Han X, Gross RW, Shayman JA: Lysosomal phospholipase A2 and phospholipidosis. Mol Cell Biol. 2006, 26: 6139-6148. 10.1128/MCB.00627-06.
Bonfield TL, Raychaudhuri B, Malur A, Abraham S, Trapnell BC, Kavuru MS, Thomassen MJ: PU.1 regulation of human alveolar macrophage differentiation requires granulocyte-macrophage colony-stimulating factor. Am J Physiol Lung Cell Mol Physiol. 2003, 285: L1132-1136.
Rotoli BM, Bussolati O, Sala R, Gazzola GC, Dall'Asta V: The transport of cationic amino acids in human airway cells: expression of system y+L activity and transepithelial delivery of NOS inhibitors. Faseb J. 2005, 19: 810-812.
Bronte V, Zanovello P: Regulation of immune responses by L-arginine metabolism. Nat Rev Immunol. 2005, 5: 641-654. 10.1038/nri1668.
Oberlies J, Watzl C, Giese T, Luckner C, Kropf P, Muller I, Ho AD, Munder M: Regulation of NK cell function by human granulocyte arginase. J Immunol. 2009, 182: 5259-5267. 10.4049/jimmunol.0803523.
Rodriguez PC, Zea AH, Culotta KS, Zabaleta J, Ochoa JB, Ochoa AC: Regulation of T cell receptor CD3zeta chain expression by L-arginine. J Biol Chem. 2002, 277: 21123-21129. 10.1074/jbc.M110675200.
Sebastio G, Fecarotta S, Sperandeo MP: Lysinuric Protein Intolerance. Gene Reviews. Edited by: Pagon RA, Bird TC, Dolan CR, Stephens K. Seattle (WA): University of Washington; 2003:.
Bronte V, Serafini P, Mazzoni A, Segal DM, Zanovello P: L-arginine metabolism in myeloid cells controls T-lymphocyte functions. Trends Immunol. 2003, 24: 302-306. 10.1016/S1471-4906(03)00132-7.
Mannucci L, Emma F, Markert M, Bachmann C, Boulat O, Carrozzo R, Rizzoni G, Dionisi-Vici C: Increased NO production in lysinuric protein intolerance. J Inherit Metab Dis. 2005, 28: 123-129. 10.1007/s10545-005-5954-x.
Luisetti M, Kadija Z, Mariani F, Rodi G, Campo I, Trapnell CB: Therapy options in pulmonary alveolar proteinosis. Ther Adv Respir Dis 2010. 2010, 4: 239-248. 10.1177/1753465810378023.
Simell O: Lysinuric protein intolerance and other cationic aminoacidurias. The Metabolic and Molecular Bases of Inherited Disease. Edited by: Scriver CR, Beaudet AL, Sly WS, Valle DT. New York: McGraw-Hill; 2001:4933-4956.
Douda DN, Farmakovski N, Dell S, Grasemann H, Palaniyar N: SP-D counteracts GM-CSF-mediated increase of granuloma formation by alveolar macrophages in lysinuric protein intolerance. Orphanet J Rare Dis. 2009, 4: 29-10.1186/1750-1172-4-29.